EuroBiotech: More Articles of Note

newspapers
(Pixabay)

> Storm Therapeutics raised £14 million ($18 million), bringing its total series A haul up to £30 million. The money will support preclinical work on modulators of RNA modifying enzymes. Release 

> Scancell revealed Cancer Research UK is planning to run a phase 1/2 trial of its SCIB2-nanoparticle complex in patients with solid tumors. Statement 

> Boehringer Ingelheim Venture Fund and UCB Ventures co-led a seed investment in hearing loss cell therapy startup Rinri Therapeutics. The British biotech will use the money to fund early-stage work on a program intended to reverse neuropathic sensorineural hearing loss. Release  

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> Slow enrollment in a pediatric trial forced Zealand Pharma to push back a planned filing for FDA approval of its dasiglucagon HypoPal rescue pen. Zealand now expects to submit a NDA early next year. Statement 

> The UKI2S Innovate Accelerator launched with £10 million to support startups in healthcare and other fields. Innovate UK and the UK Innovation & Science Seed Fund joined forces to set up the accelerator. Release 

Suggested Articles

NGM's aldafermin beat placebo at reversing liver scarring and inflammation, as well as reducing liver fat buildup in a 78-patient study.

The agreement sees Grifols waive a $32 million debt and pay $3 million in cash to take full ownership of three assets.

Astellas’ Xospata and Novartis’ Rydapt may help treat lung cancer that has grown resistant to EGFR inhibitors, researchers discovered.